	US 11,931,372 B2
	Pharmaceutical composition containing pentacyclic triterpenoids
Ulises Zendejas Hernandez, Ixtapaluca (MX); Alicia Teresa Smith Ogarrio, Mexico City (MX); and Mercedes Gutiérrez Smith, Mexico City (MX)
Assigned to SPV TIMSER, S.A.P.I. DE C.V., Mexico City (MX)
Appl. No. 17/923,776
Filed by SPV TIMSER, S.A.P.I. DE C.V., Mexico City (MX)
PCT Filed Mar. 25, 2022, PCT No. PCT/MX2022/050031 § 371(c)(1), (2) Date Nov. 7, 2022, PCT Pub. No. WO2022/235146, PCT Pub. Date Nov. 10, 2022.
Claims priority of application No. MX/a/2021/005280 (MX), filed on May 4, 2021.
Prior Publication US 2023/0210876 A1, Jul. 6, 2023
Int. Cl. A61K 31/704 (2006.01); A61K 31/19 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61P 31/12 (2006.01)

CPC A61K 31/704 (2013.01) [A61K 31/19 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61P 31/12 (2018.01)]

15 Claims

1. A pharmaceutical composition that comprises a synergistic combination of at least two pentacyclic triterpenoids to be used for the treatment of viral infections, wherein

the at least two pentacyclic triterpenoids comprise 18β-glycyrrhetinic acid and glycyrrhizinic acid; and

a ratio of the 18β-glycyrrhetinic acid to the glycyrrhizinic acid is 1:5 to 1:25.